期刊文献+

川芎嗪调节Bcl-2促进帕金森病小鼠多巴胺神经元存活 被引量:5

Effect of tetramethy lpyrazine-administration on tyrosine hydroxylase in midbrain of Parkinson disease mice model
下载PDF
导出
摘要 目的探讨川芎嗪对PD小鼠多巴胺神经元的保护作用。方法 30只健康雄性C57BL/6小鼠,随机分为正常对照组、模型组和治疗组。模型组和治疗组给予腹腔注射百草枯和代森锰建立PD模型,建模成功后,治疗组给予川芎嗪腹腔注射2 w,正常对照组给予同剂量生理盐水。观察3组小鼠行为学的改变、并用免疫组织化学、Western印迹法检测中脑多巴胺神经元数量、形态参数及Bcl-2的表达。结果模型组与治疗组比较,爬杆时间明显延长,中脑多巴胺神经元数量显著减少、Bcl-2的表达显著增高。结论川芎嗪治疗可上调Bcl-2的表达,增加黑质TH阳性神经元数量,有明显的神经保护作用。 Objective To investigate the effect of Tetramethy Lpyrazine on tyrosine hydroxylase(TH) in midbrain of Parkinson dis-ease(PD) mice model induced by paraquat and maneb. Methods Male C57BL/6 mices were randomly divided into PQ + MN treated, Tet-ramethy Lpyrazine treated and control groups. Behavioral, immunohistochmical and western blot were used to detect the motor coordination and the expressions of TH, bcl-2 in midbrain. Results Administration of Tetramethy Lpyrazine could significantly attenuate the impairment of behavioral performance, increase the expression of TH and bcl-2 in midbrain. Conclusions Tetramethy Lpyrazine has a beneficial influ- ence on parkinsonism by increase bcl-2 in midbrain.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2013年第17期4173-4175,共3页 Chinese Journal of Gerontology
基金 贵州省科技厅联合基金项目〔黔科合LG字(2011)023号〕 贵州省社会发展科技攻关计划项目〔黔科合SY字(2008)3046号〕
关键词 帕金森病 川芎嗪 百草枯 代森锰 BCL-2 Parkinson disease Tetramethy Lpyrazine Praquat Maneb Bcl-2
  • 相关文献

参考文献16

  • 1Pan-Monlojo F, Anichtehik O, Dening Y,et al. Progression of Parkinson's disease pathology is reprodueed by intragastrie administration of rotenone in mice[J]. PlxS One,2010;5(1 ) :e8762.
  • 2Rijk MC, Launer LJ, Berger K,et al. Prevalence of Parkinson's disease in Europe:a collaborative study of population-based cohorts. Neurologic Disea- ses in the Elderly Research Group[J]. Neurolog?,2000;54( 11 ):$21-3.
  • 3Braak H, Del Tredici K, Rub U ,et al. Staging of brain pathology related to sporadic Parkinson' s disease [ J]. Neurobiol Aging. 2003 ; 24 ( 2 ) : 197- 211.
  • 4Eberhardt O,Sehula JB. Apoptotie mechanisms and ant.iapoptotic' therapy in the MPTP mMel of Parkinson's disease[ J]. Toxicol l,ett ,2004 ; 139 (2- 3) :135-51.
  • 5唐泽耀,王世龙,林原.川穹嗪在神经系统的药代动力学及临床药效学应用研究进展[J].中国临床药理学杂志,2010,26(7):535-539. 被引量:25
  • 6Kao TK,Ou YC, Kuo JS, et al. Neuroprotection by' tetramethylpyrazine a- gainst ischemic brain injury in rats[ J]. Neurochem lnt, 2006;d8 (3): 166 -76.
  • 7Gao C, Liu X, Liu W, el +11. Anti-apoplotic and neut'prolet'tive cfl-'cls of Tetramethylpyrazine following subarachnoid hemorrhage in rats[J]. Auton Neurosci ,2008 ; 141 ( 1-2 ) :22-30.
  • 8'Fay or TN,Greene JG,Miller GW. Behavioral phenol?ping of mouse mod- els of Parkinson's disease[J]. Behav Brain Res 2010;211 ( 1) :1-10.
  • 9Ogawa N, Hirose Y, Ohara S ,et al. A simple quantitative bradykinesia test in MPTP-treated mice[J]. Res Conmmn Chem Pathol Phannacol, 1985: 50( 3 ) :435-41.
  • 10Fei Q,Ethell I)W. Maneb potentiates paraquat neurotoxicit, by inducing key Bcl-2 family members[ J ]. J Neurchem ,2008 ; 105 ( 6 ) :2091-7.

二级参考文献22

共引文献24

同被引文献91

  • 1王丹巧,王巍,景富春,赵晋宁.川芎嗪对左旋多巴处理的PD大鼠纹状体细胞外液DA及其代谢产物、羟自由基水平的影响[J].中国药学杂志,2007,42(1):28-32. 被引量:18
  • 2JIN HJ,Kanthasamy A,Ghosh A,et al.Mitochondria-targeted antioxidants for treatment of Parkinson's disease:Preclinical and clinical outcomes.Biochim Biophys Acta,2013,http://dx.doi.org/10.1016/j.bbadis.2013.09.007.
  • 3Hauser DN,Hastings TG.Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.Neurobiology of Disease,2013,51:35-42.
  • 4Zhang X,Li L,Zhang L,et al.Cyanide-induced death of dopaminergic cells is mediated by uncoupling protein-2 up-regulation and reduced Bcl-2 expression.Toxicol Appl Pharmacol,2009,238(1):11-19.
  • 5Lee EH, Seo SR. Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases[J]. BMB Rep, 201.4, 47(7): 369-376.
  • 6Santos NA, Martins NM, Silva RB, et al. Caffeic acid phenethyl ester (CAPE) protects PC12 cells from MPP+ toxicity by indu- cing the expression of neuron-typical proteins[J]. Neurotoxicol- ogy, 2014, 45.. 131-138.
  • 7Massano J, Bhatia KP. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management [J]. Cold Spring Harb Perspect Med, 2012, 2(6): a008870.
  • 8Mena MA, Casarejos MJ, Solano RM, et al. Half a century of L -DOPA[J]. Curr Top Med Chem, 2009, 9(10) : 880-893.
  • 9Qing H. The ability of atypical antipsychotic drugs vs haloperi- dol to protect PC12 cells against MPP+-induced apoptosis[J]. Eur J Neurosci, 2003, 17(8) : 1563-1570.
  • 10Waschek JA. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair[J]. Br J Pharmacol, 2013, 169 (3) : 512-523.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部